Image

Cervavac HPV Vaccine: Types, Age Group and WHO Status

Cervavac HPV Vaccine: Types, Age Group and WHO Status

Overview :

Cervavac, India’s first indigenous gender-neutral quadrivalent HPV vaccine, has received WHO prequalification. Know its HPV types, age group, developer and exam facts.

Cervavac: India’s First Indigenous

Cervavac , India’s first indigenously developed gender-neutral quadrivalent HPV vaccine, has received WHO prequalification . The vaccine was developed by the Serum Institute of India in Pune . It targets four HPV types: 6, 11, 16 and 18 .

What is WHO Prequalification?

WHO prequalification is a quality check for medicines, vaccines and diagnostic products. Think of it as a global quality stamp. It helps United Nations agencies and public health programmes consider these products for procurement.

What is Cervavac?

Cervavac is a quadrivalent HPV vaccine . “Quadrivalent” means that it protects against four HPV types. The vaccine is meant for girls and boys aged 9 to 26 years . It helps prevent HPV-related cancers and genital warts linked to the targeted virus types.

Which HPV Types Does Cervavac Target?

Cervavac targets HPV 6, 11, 16 and 18 . HPV types 16 and 18 are linked with several cancers. Types 6 and 11 are linked with genital warts. This makes the vaccine useful for protection against different HPV-related health problems.

Who Developed Cervavac?

Serum Institute of India developed Cervavac with support from several organisations. These include the Department of Biotechnology, Biotechnology Industry Research Assistance Council, WHO International Agency for Research on Cancer and Bill & Melinda Gates Foundation .

Approval and Launch in India

India’s Drugs Controller General of India (DCGI) approved Cervavac for use in the country. Serum Institute launched the vaccine nationally on 24 January 2023 . Its WHO prequalification now adds another step to its global journey.

Why is WHO Prequalification Important?

WHO prequalification can help a vaccine enter international public health procurement systems. Cervavac also adds to India’s role in the global vaccine supply chain. India’s biotechnology sector, startups and research institutions continue to support work in vaccines, diagnostics and other health technologies.

Exam-Focused Points :

  • Vaccine: Cervavac.

  • Developer: Serum Institute of India.

  • Location: Pune, Maharashtra.

  • Type: Gender-neutral quadrivalent HPV vaccine.

  • HPV types targeted: 6, 11, 16 and 18.

  • Age group: Girls and boys aged 9–26 years .

  • WHO prequalification: Helps UN agencies consider vaccines for procurement.

FAQs :

Q1. What is Cervavac?

Answer: Cervavac is an indigenous quadrivalent HPV vaccine developed by the Serum Institute of India.

Q2. Which HPV types does Cervavac target?

Answer: It targets HPV 6, 11, 16 and 18 .

Q3. Who can receive Cervavac?

Answer: The vaccine is indicated for girls and boys aged 9 to 26 years .

Q4. What does quadrivalent mean?

Answer: It means the vaccine targets four HPV types .

Q5. When was Cervavac launched nationally in India?

Answer: It was launched nationally on 24 January 2023 .

Month: 

Category: 

1